Patents Assigned to Biomethodes
  • Patent number: 9903873
    Abstract: The invention relates to a method for selecting proteins stable in non-standard physicochemical conditions (temperature, pressure, pH, osmolarity, salinity, solvent, etc.) comprising the expression, in an extremophilic microorganism, of variants of the protein of interest in the form of a fusion protein with a reporter protein which is stable in extreme conditions and acts as a selection marker.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: February 27, 2018
    Assignee: BIOMETHODES
    Inventor: Marc Delcourt
  • Patent number: 9637728
    Abstract: The present invention provides T. reesei endoglucanase I variants exhibiting improved cellulase and/or xylanase activity, in particular at 30° C. and/or pH 6. These variants are particularly useful in industrial processes comprising simultaneous degradation of cellulosic biomass into monomeric sugars and fermentation of said sugars, for example to produce ethanol.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: May 2, 2017
    Assignee: BIOMETHODES
    Inventors: Stéphane Blesa, Céline Coursange, Bruno Winter
  • Patent number: 9109210
    Abstract: The present invention provides the field of enhancing proteins and in particular to that of proteins enhanced by molecular change. It provides a variant of a phytase that is termed enhanced in that is has better thermostability and/or activity than the original phytase. The invention also provides a nucleic acid coding for said variant, a cassette or an expression vector containing said variant, a host cell expressing said variant, a composition comprising said variant and uses thereof, principally in the preparation of food additives and animal feed.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: August 18, 2015
    Assignee: BIOMETHODES
    Inventors: Stephane Blesa, Helene Chautard, Marc Delcourt, Laurent Mesta, Bruno Winter
  • Patent number: 8623824
    Abstract: The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: January 7, 2014
    Assignees: Biomethodes, Hospices Civils de Lyon
    Inventors: Didier Saboulard, Jean-Luc Plantier, Marc Delcourt, Claude Negrier, Thierry Menguy, Stephane Blesa, Sylvie Marin
  • Publication number: 20130122567
    Abstract: The present invention provides the field of enhancing proteins and in particular to that of proteins enhanced by molecular change. It provides a variant of a phytase that is termed enhanced in that is has better thermostability and/or activity than the original phytase. The invention also provides a nucleic acid coding for said variant, a cassette or an expression vector containing said variant, a host cell expressing said variant, a composition comprising said variant and uses thereof, principally in the preparation of food additives and animal feed.
    Type: Application
    Filed: July 1, 2010
    Publication date: May 16, 2013
    Applicant: BIOMETHODES
    Inventors: Stephane Blesa, Helene Chautard, Marc Delcourt, Laurent Mesta, Bruno Winter
  • Publication number: 20100311659
    Abstract: The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.
    Type: Application
    Filed: February 22, 2008
    Publication date: December 9, 2010
    Applicants: BIOMETHODES, HOSPICES CIVILS DE LYON
    Inventors: Didier Saboulard, Jean-Luc Plantier, Marc Delcourt, Claude Negrier, Thierry Menguy, Stephane Blesa, Sylvie Marin
  • Publication number: 20100260704
    Abstract: The present invention relates to human interferon gamma variants with improved thermostability, to a nucleic acid encoding said variants, to a pharmaceutical composition containing them, and to their use for the treatment of a viral infection and of cancer.
    Type: Application
    Filed: March 8, 2007
    Publication date: October 14, 2010
    Applicant: BIOMETHODES
    Inventors: Jose Berenguer, Marc Delcourt, Héléne Chautard, Thierry Menguy
  • Publication number: 20090131264
    Abstract: The invention relates to a method for selecting proteins stable in non-standard physicochemical conditions (temperature, pressure, pH, osmolarity, salinity, solvent, etc.) comprising the expression, in an extremophilic microorganism, of variants of the protein of interest in the form of a fusion protein with a reporter protein which is stable in extreme conditions and acts as a selection marker.
    Type: Application
    Filed: April 4, 2006
    Publication date: May 21, 2009
    Applicant: BIOMETHODES
    Inventor: Marc Delcourt
  • Patent number: 7202086
    Abstract: The invention concerns the field of molecular biology and more particularly that of mutagenesis. It concerns a method of high-rate directed mutagenesis, that is the formation of numerous directed mutants in reduced time and with reduced number of steps. Said method is therefore referred to as massive mutagenesis.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: April 10, 2007
    Assignee: Biomethodes
    Inventors: Marc Delcourt, Stephane Blesa
  • Patent number: 6924112
    Abstract: The present invention pertains to a process for isolating an intact clone of one target nucleic acid fragment having a known characteristic, from a group of fragments by preparing an initial library of clones from the group of fragments using a vector containing no more than a predetermined number of known restriction sites, preferably 1–3 restriction sites, subjecting the initial library to at least 10, and preferably between 50 and 70 restriction enzymes different from those to which the vector is susceptible, to produce a group of monodigested libraries, screening the group of monodigested libraries for the target fragment to determine those restriction enzymes to which the target fragment is insensitive, and subjecting the initial library to substantially all of the restriction enzymes to which the target fragment is insensitive, to produce a multidigested library having an intact clone of the target nucleic acid fragment.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: August 2, 2005
    Assignee: Biomethodes S.A.R.L.
    Inventor: Marc Delcourt
  • Publication number: 20050153343
    Abstract: The invention relates to the field of molecular biology and more particularly that of mutagenesis. The invention has as its object a method of high throughput directed mutagenesis, that is to say, constitution of a large number of directed mutants at a reduced cost, time and number of steps. The invention also relates to the double stranded polynucleotides so obtained and the peptides, polypeptides, or proteins so obtained having one or more improved properties, and the uses of said method.
    Type: Application
    Filed: December 15, 2004
    Publication date: July 14, 2005
    Applicant: BIOMETHODES
    Inventors: Julien Sylvestre, Marc Delcourt